TickerTalks
Browse all tickers →
TickerTalks›$AMGN
AMAMGN

Amgen Inc.

$AMGN·$196B·Drug Manufacturers - General·Healthcare
$366.29-1.4%YTD+11.4%1Y+22.8%
Mentions · last 7 days
2026-07-10: 188 posts2026-07-11: 68 posts2026-07-12: 125 posts2026-07-13: 206 posts2026-07-14: 94 posts2026-07-15: 129 posts2026-07-16: 107 posts936+4%
Price updated 5h ago·X counts updated 1d ago
AMAMGN
$AMGNAmgen Inc.
$366.29-1.42%936 posts+4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AMGN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-07-17

The move is getting stronger, with heavier trading behind it.

Big-cap biotech quietly compounding into a Q2 print with AI-manufacturing and M&A speculation on the tape.

Amgen is one of the two largest US-listed pure biotechs — Repatha, Enbrel, Prolia, Blincyto, and increasingly a strong obesity/immunology pipeline led by MariTide (Amgen's GLP-1 obesity asset) and various oncology bispecifics. The equity had been range-bound for a decade; the last year has finally started to break the pattern.

Why the setup has re-rated:

  • Growth is stabilizing at mid-single digits: Q1 revenue up 5.8% YoY, four-quarter stack 6-12% — Amgen is not a growth stock, but the deceleration risk has receded.
  • Margins are exceptional and stable: operating margin 32% and gross margin 71% — this is what a mature biotech with the right cost base looks like when the top line grows.
  • The multiple is reasonable: 24x trailing earnings and 17x FY27 consensus EPS of $22.35 — genuinely fair for a business at this scale and margin profile.
  • The AI-manufacturing narrative is real: the ATOMIC AI model for site selection (2.5-3x better patient enrollment) plus the AI-infused Ohio/NC protein-therapeutic manufacturing footprint is a genuine operational-leverage story, not just marketing.
  • M&A speculation is directional: the Vera Therapeutics speculation ahead of atacicept's FDA decision is exactly the type of tuck-in that Amgen historically pursues to reinforce a franchise.
  • Position confirms the setup: 84% of the 52-week range, YTD +13%, t12m +24% — the compounder narrative is being paid for.

The forward view: the August 4 Q2 print is the referee. A beat with continued Repatha/Blincyto/Enbrel strength plus specific MariTide obesity-program updates is what keeps the accelerating leg alive. What breaks it: a specific MariTide safety headline, or a Vera Therapeutics deal that lands at a price the market judges dilutive.

Agrees with X sentimentThe bullish X read on the ATOMIC AI framing, the Vera Therapeutics M&A speculation, and the AI-manufacturing footprint is directionally right. Our take agrees the compounder is finally being paid for.

What to watch: August 4 Q2 earnings, plus any MariTide obesity-trial update or Vera Therapeutics deal announcement; a MariTide safety headline or an over-priced deal would end the accelerating leg.

On the calendar: 2026-08-04 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-13

Amgen's ex-CTO Dave Reese and EVP R&D Jay Bradner described the ATOMIC AI model that selects trial sites 2.5x-3x more likely to enroll appropriate patients. Amgen is repeatedly framed as a likely M&A contender for Vera Therapeutics ahead of Atacicept's FDA decision, and its Ohio and North Carolina plants are heavily infused with AI and machine learning for protein-therapeutic manufacturing.

Read the AI verdict + X sentiment for $AMGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops biologics for oncology, cardiovascular, bone health, and inflammation with a growing biosimilar portfolio and obesity pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $AMGN.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $AMGN

Direct beneficiary — Develops biologics for oncology, cardiovascular, bone health, and inflammation with a growing biosimilar portfolio and obesity pipeline; the company is structurally positioned to capture the oral GLP-1 and obesity pipeline expansion and competition.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+18.7%YTD
+49.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
24.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
31.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
89.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
71.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
6.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$5.15$4.77+8.0%
Q4 2025Feb 3, 2026$5.29$4.73+11.8%
Q3 2025Nov 4, 2025$5.64$5.02+12.4%
Q2 2025Aug 5, 2025$6.02$5.28+14.0%
Next earningsTue, Aug 4·consensus EPS $5.58

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$8.6B+5.8%68.2%30.9%$3.37$1.5B
Q4 FY25$9.9B+8.9%81.9%39.8%$2.47$961.0M
Q3 FY25$9.6B+12.4%67.8%26.4%$5.98$4.2B
Q2 FY25$9.2B+9.3%67.2%28.8%$2.66$1.9B

Forward consensus

5-year forecast · up to 27 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$37.8B$37.3B – $38.3B$22.35$20.68 – $22.7624
FY27$38.8B$37.7B – $40.0B$23.41$21.15 – $24.4824
FY28$39.8B$39.8B – $39.8B$24.36$19.21 – $30.7227
FY29$41.1B$40.1B – $42.7B$25.81$24.96 – $27.1013
FY30$42.7B$41.6B – $44.3B$27.43$26.53 – $28.8013

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.79%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+5.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 538.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.405-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 49 other (25 awards · 24 inkinds) in window

See when $AMGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 208-K — Item 5.07: Shareholder vote
AI summary

Amgen Inc. (AMGN) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an advisory say-on-pay resolution, ratification of the independent auditor, shareholder proposals. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

8-KOfficer or director changeMay 198-K — Item 5.02: Officer or director change
AI summary

Amgen Inc. (AMGN) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in Chief Executive Officer. Individuals named in the filing include Amgen Inc, Its Charter. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeApr 228-K — Item 5.02: Officer or director change
AI summary

AMGN disclosed a personnel change (8-K Item 5.02, dated 2026-04-22). An executive departure and a new appointment are both reported. President and Chief Technology Officer. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KMaterial agreementFeb 198-K — Item 1.01: Material agreement
S-3ASRAuto-shelf registrationFeb 13S-3ASR
8-KAgreement terminatedJan 308-K — Item 1.02: Agreement terminated
+ 15 other (4 proxys · 3 13Gs · 2 11-Ks · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?247wallst.com·16h agoWill Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?zacks.com·2d agoAmgen (AMGN) Stock Sinks As Market Gains: What You Should Knowzacks.com·3d agoHRMY vs. AMGN: Which Stock Is the Better Value Option?zacks.com·4d agoPfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen247wallst.com·4d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$PFE$MRK$ABBV$GILD$OGN
Voices on X · last 7 days

No standout posts about $AMGN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport